lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway
Identifieur interne : 000228 ( Pmc/Checkpoint ); précédent : 000227; suivant : 000229lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway
Auteurs : Yongchao Li [République populaire de Chine] ; Changfeng Li ; Dandan Li ; Lei Yang ; Jingpeng Jin ; Bin ZhangSource :
- OncoTargets and therapy [ 1178-6930 ] ; 2019.
Abstract
The chemoresistance of colon cancer to oxaliplatin (L-OHP) indicates poor prognosis. Long non-coding RNA (lncRNA) KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) has been shown to participate in the tumorigenesis of several types of cancers. However, little is known about the role of KCNQ1OT1 in the chemoresistance and prognosis of colon cancer.
Quantitative-PCR and Western blot were used to measure the expression profiles of KCNQ1OT1, miR-34a, and Atg4B in colon cancer tissues and cells. Cell viability assay and flow cytometry were used to examine their effects on cell proliferation and death. Cleavage of LC3 and GFP-LC3 plasmid transfection were used to detect autophagic activity. Double luciferase reporter assay was used to verify the interactions between miRNA and lncRNA or mRNA. Xenograft tumor model was used to verify the effects of KCNQ1OT1 in vivo.
In this study, it is shown that the expression level of KCNQ1OT1 was increased in tumor, which indicated poor prognosis in colon cancer patients. Using colon cancer cell lines HCT116 and SW480, it was demonstrated that knockdown of KCNQ1OT1 decreased the cell viability and increased the apoptosis rates upon L-OHP treatment. Further studies indicated that Atg4B upregulation was partially responsible for KCNQ1OT1-induced protective autophagy and chemoresistance. Moreover, miR-34a functioned as a bridge between KCNQ1OT1 and Atg4B, which could be sponged by KCNQ1OT1, while it could also bind to the 3′-UTR of Atg4B and downregulate its expressions. Finally, we show that the KCNQ1OT1/miR-34a/Atg4B axis regulated the chemoresistance of colon cancer cells in vitro and in vivo.
lncRNA KCNQ1OT1 promoted the chemoresistance of colon cancer by sponging miR-34a, thus upregulating the expressions of Atg4B and enhancing protective autophagy. KCNQ1OT1 might become a promising target for colon cancer therapeutics.
Url:
DOI: 10.2147/OTT.S188054
PubMed: 31040703
PubMed Central: 6462170
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:6462170Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway</title><author><name sortKey="Li, Yongchao" sort="Li, Yongchao" uniqKey="Li Y" first="Yongchao" last="Li">Yongchao Li</name><affiliation wicri:level="1"><nlm:aff id="af1-ott-12-2649">Department of Gastrointestinal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Gastrointestinal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033</wicri:regionArea><wicri:noRegion>Jilin 130033</wicri:noRegion></affiliation></author><author><name sortKey="Li, Changfeng" sort="Li, Changfeng" uniqKey="Li C" first="Changfeng" last="Li">Changfeng Li</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Li, Dandan" sort="Li, Dandan" uniqKey="Li D" first="Dandan" last="Li">Dandan Li</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Yang, Lei" sort="Yang, Lei" uniqKey="Yang L" first="Lei" last="Yang">Lei Yang</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Jin, Jingpeng" sort="Jin, Jingpeng" uniqKey="Jin J" first="Jingpeng" last="Jin">Jingpeng Jin</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Zhang, Bin" sort="Zhang, Bin" uniqKey="Zhang B" first="Bin" last="Zhang">Bin Zhang</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31040703</idno><idno type="pmc">6462170</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462170</idno><idno type="RBID">PMC:6462170</idno><idno type="doi">10.2147/OTT.S188054</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000747</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000747</idno><idno type="wicri:Area/Pmc/Curation">000747</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000747</idno><idno type="wicri:Area/Pmc/Checkpoint">000228</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000228</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway</title><author><name sortKey="Li, Yongchao" sort="Li, Yongchao" uniqKey="Li Y" first="Yongchao" last="Li">Yongchao Li</name><affiliation wicri:level="1"><nlm:aff id="af1-ott-12-2649">Department of Gastrointestinal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Gastrointestinal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033</wicri:regionArea><wicri:noRegion>Jilin 130033</wicri:noRegion></affiliation></author><author><name sortKey="Li, Changfeng" sort="Li, Changfeng" uniqKey="Li C" first="Changfeng" last="Li">Changfeng Li</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Li, Dandan" sort="Li, Dandan" uniqKey="Li D" first="Dandan" last="Li">Dandan Li</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Yang, Lei" sort="Yang, Lei" uniqKey="Yang L" first="Lei" last="Yang">Lei Yang</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Jin, Jingpeng" sort="Jin, Jingpeng" uniqKey="Jin J" first="Jingpeng" last="Jin">Jingpeng Jin</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author><author><name sortKey="Zhang, Bin" sort="Zhang, Bin" uniqKey="Zhang B" first="Bin" last="Zhang">Bin Zhang</name><affiliation><nlm:aff id="af2-ott-12-2649">Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></nlm:aff></affiliation></author></analytic><series><title level="j">OncoTargets and therapy</title><idno type="eISSN">1178-6930</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>The chemoresistance of colon cancer to oxaliplatin (L-OHP) indicates poor prognosis. Long non-coding RNA (lncRNA) KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) has been shown to participate in the tumorigenesis of several types of cancers. However, little is known about the role of KCNQ1OT1 in the chemoresistance and prognosis of colon cancer.</p></sec><sec><title>Materials and methods</title><p>Quantitative-PCR and Western blot were used to measure the expression profiles of KCNQ1OT1, miR-34a, and Atg4B in colon cancer tissues and cells. Cell viability assay and flow cytometry were used to examine their effects on cell proliferation and death. Cleavage of LC3 and GFP-LC3 plasmid transfection were used to detect autophagic activity. Double luciferase reporter assay was used to verify the interactions between miRNA and lncRNA or mRNA. Xenograft tumor model was used to verify the effects of KCNQ1OT1 in vivo.</p></sec><sec><title>Results</title><p>In this study, it is shown that the expression level of KCNQ1OT1 was increased in tumor, which indicated poor prognosis in colon cancer patients. Using colon cancer cell lines HCT116 and SW480, it was demonstrated that knockdown of KCNQ1OT1 decreased the cell viability and increased the apoptosis rates upon L-OHP treatment. Further studies indicated that Atg4B upregulation was partially responsible for KCNQ1OT1-induced protective autophagy and chemoresistance. Moreover, miR-34a functioned as a bridge between KCNQ1OT1 and Atg4B, which could be sponged by KCNQ1OT1, while it could also bind to the 3′-UTR of Atg4B and downregulate its expressions. Finally, we show that the KCNQ1OT1/miR-34a/Atg4B axis regulated the chemoresistance of colon cancer cells in vitro and in vivo.</p></sec><sec><title>Conclusion</title><p>lncRNA KCNQ1OT1 promoted the chemoresistance of colon cancer by sponging miR-34a, thus upregulating the expressions of Atg4B and enhancing protective autophagy. KCNQ1OT1 might become a promising target for colon cancer therapeutics.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Siegel, R" uniqKey="Siegel R">R Siegel</name></author><author><name sortKey="Desantis, C" uniqKey="Desantis C">C Desantis</name></author><author><name sortKey="Jemal, A" uniqKey="Jemal A">A Jemal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, W" uniqKey="Chen W">W Chen</name></author><author><name sortKey="Zheng, R" uniqKey="Zheng R">R Zheng</name></author><author><name sortKey="Baade, Pd" uniqKey="Baade P">PD Baade</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kelland, L" uniqKey="Kelland L">L Kelland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martinez Balibrea, E" uniqKey="Martinez Balibrea E">E Martinez-Balibrea</name></author><author><name sortKey="Martinez Cardus, A" uniqKey="Martinez Cardus A">A Martinez-Cardus</name></author><author><name sortKey="Gines, A" uniqKey="Gines A">A Gines</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Z" uniqKey="Yang Z">Z Yang</name></author><author><name sortKey="Klionsky, Dj" uniqKey="Klionsky D">DJ Klionsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Y" uniqKey="Wu Y">Y Wu</name></author><author><name sortKey="Ni, Z" uniqKey="Ni Z">Z Ni</name></author><author><name sortKey="Yan, X" uniqKey="Yan X">X Yan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kumar, A" uniqKey="Kumar A">A Kumar</name></author><author><name sortKey="Singh, Uk" uniqKey="Singh U">UK Singh</name></author><author><name sortKey="Chaudhary, A" uniqKey="Chaudhary A">A Chaudhary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Quinn, Jj" uniqKey="Quinn J">JJ Quinn</name></author><author><name sortKey="Chang, Hy" uniqKey="Chang H">HY Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagano, T" uniqKey="Nagano T">T Nagano</name></author><author><name sortKey="Fraser, P" uniqKey="Fraser P">P Fraser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thomson, Dw" uniqKey="Thomson D">DW Thomson</name></author><author><name sortKey="Dinger, Me" uniqKey="Dinger M">ME Dinger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kallen, An" uniqKey="Kallen A">AN Kallen</name></author><author><name sortKey="Zhou, Xb" uniqKey="Zhou X">XB Zhou</name></author><author><name sortKey="Xu, J" uniqKey="Xu J">J Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Korostowski, L" uniqKey="Korostowski L">L Korostowski</name></author><author><name sortKey="Sedlak, N" uniqKey="Sedlak N">N Sedlak</name></author><author><name sortKey="Engel, N" uniqKey="Engel N">N Engel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pandey, Rr" uniqKey="Pandey R">RR Pandey</name></author><author><name sortKey="Mondal, T" uniqKey="Mondal T">T Mondal</name></author><author><name sortKey="Mohammad, F" uniqKey="Mohammad F">F Mohammad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ren, K" uniqKey="Ren K">K Ren</name></author><author><name sortKey="Xu, R" uniqKey="Xu R">R Xu</name></author><author><name sortKey="Huang, J" uniqKey="Huang J">J Huang</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author><author><name sortKey="Shi, W" uniqKey="Shi W">W Shi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, C" uniqKey="Li C">C Li</name></author><author><name sortKey="Miao, R" uniqKey="Miao R">R Miao</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J Zhang</name></author><author><name sortKey="Qu, K" uniqKey="Qu K">K Qu</name></author><author><name sortKey="Liu, C" uniqKey="Liu C">C Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, C" uniqKey="Li C">C Li</name></author><author><name sortKey="Gao, Y" uniqKey="Gao Y">Y Gao</name></author><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Ding, D" uniqKey="Ding D">D Ding</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, C" uniqKey="Li C">C Li</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Cheng, X" uniqKey="Cheng X">X Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Workman, P" uniqKey="Workman P">P Workman</name></author><author><name sortKey="Aboagye, Eo" uniqKey="Aboagye E">EO Aboagye</name></author><author><name sortKey="Balkwill, F" uniqKey="Balkwill F">F Balkwill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hemelaar, J" uniqKey="Hemelaar J">J Hemelaar</name></author><author><name sortKey="Lelyveld, Vs" uniqKey="Lelyveld V">VS Lelyveld</name></author><author><name sortKey="Kessler, Bm" uniqKey="Kessler B">BM Kessler</name></author><author><name sortKey="Ploegh, Hl" uniqKey="Ploegh H">HL Ploegh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paraskevopoulou, Md" uniqKey="Paraskevopoulou M">MD Paraskevopoulou</name></author><author><name sortKey="Vlachos, Is" uniqKey="Vlachos I">IS Vlachos</name></author><author><name sortKey="Karagkouni, D" uniqKey="Karagkouni D">D Karagkouni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maiuri, Mc" uniqKey="Maiuri M">MC Maiuri</name></author><author><name sortKey="Zalckvar, E" uniqKey="Zalckvar E">E Zalckvar</name></author><author><name sortKey="Kimchi, A" uniqKey="Kimchi A">A Kimchi</name></author><author><name sortKey="Kroemer, G" uniqKey="Kroemer G">G Kroemer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sugawara, K" uniqKey="Sugawara K">K Sugawara</name></author><author><name sortKey="Suzuki, Nn" uniqKey="Suzuki N">NN Suzuki</name></author><author><name sortKey="Fujioka, Y" uniqKey="Fujioka Y">Y Fujioka</name></author><author><name sortKey="Mizushima, N" uniqKey="Mizushima N">N Mizushima</name></author><author><name sortKey="Ohsumi, Y" uniqKey="Ohsumi Y">Y Ohsumi</name></author><author><name sortKey="Inagaki, F" uniqKey="Inagaki F">F Inagaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Satoo, K" uniqKey="Satoo K">K Satoo</name></author><author><name sortKey="Noda, Nn" uniqKey="Noda N">NN Noda</name></author><author><name sortKey="Kumeta, H" uniqKey="Kumeta H">H Kumeta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bortnik, S" uniqKey="Bortnik S">S Bortnik</name></author><author><name sortKey="Choutka, C" uniqKey="Choutka C">C Choutka</name></author><author><name sortKey="Horlings, Hm" uniqKey="Horlings H">HM Horlings</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, S" uniqKey="Wu S">S Wu</name></author><author><name sortKey="Su, J" uniqKey="Su J">J Su</name></author><author><name sortKey="Qian, H" uniqKey="Qian H">H Qian</name></author><author><name sortKey="Guo, T" uniqKey="Guo T">T Guo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liao, H" uniqKey="Liao H">H Liao</name></author><author><name sortKey="Xiao, Y" uniqKey="Xiao Y">Y Xiao</name></author><author><name sortKey="Hu, Y" uniqKey="Hu Y">Y Hu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang, Z" uniqKey="Yang Z">Z Yang</name></author><author><name sortKey="Wilkie Grantham, Rp" uniqKey="Wilkie Grantham R">RP Wilkie-Grantham</name></author><author><name sortKey="Yanagi, T" uniqKey="Yanagi T">T Yanagi</name></author><author><name sortKey="Shu, Cw" uniqKey="Shu C">CW Shu</name></author><author><name sortKey="Matsuzawa, S" uniqKey="Matsuzawa S">S Matsuzawa</name></author><author><name sortKey="Reed, Jc" uniqKey="Reed J">JC Reed</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ni, Z" uniqKey="Ni Z">Z Ni</name></author><author><name sortKey="He, J" uniqKey="He J">J He</name></author><author><name sortKey="Wu, Y" uniqKey="Wu Y">Y Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rafiee, A" uniqKey="Rafiee A">A Rafiee</name></author><author><name sortKey="Riazi Rad, F" uniqKey="Riazi Rad F">F Riazi-Rad</name></author><author><name sortKey="Havaskary, M" uniqKey="Havaskary M">M Havaskary</name></author><author><name sortKey="Nuri, F" uniqKey="Nuri F">F Nuri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Higashimoto, K" uniqKey="Higashimoto K">K Higashimoto</name></author><author><name sortKey="Soejima, H" uniqKey="Soejima H">H Soejima</name></author><author><name sortKey="Saito, T" uniqKey="Saito T">T Saito</name></author><author><name sortKey="Okumura, K" uniqKey="Okumura K">K Okumura</name></author><author><name sortKey="Mukai, T" uniqKey="Mukai T">T Mukai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, S" uniqKey="Zhang S">S Zhang</name></author><author><name sortKey="Ma, H" uniqKey="Ma H">H Ma</name></author><author><name sortKey="Zhang, D" uniqKey="Zhang D">D Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu, Qb" uniqKey="Wu Q">QB Wu</name></author><author><name sortKey="Sheng, X" uniqKey="Sheng X">X Sheng</name></author><author><name sortKey="Zhang, N" uniqKey="Zhang N">N Zhang</name></author><author><name sortKey="Yang, Mw" uniqKey="Yang M">MW Yang</name></author><author><name sortKey="Wang, F" uniqKey="Wang F">F Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Misso, G" uniqKey="Misso G">G Misso</name></author><author><name sortKey="Di Martino, Mt" uniqKey="Di Martino M">MT Di Martino</name></author><author><name sortKey="De Rosa, G" uniqKey="De Rosa G">G De Rosa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Xj" uniqKey="Li X">XJ Li</name></author><author><name sortKey="Ren, Zj" uniqKey="Ren Z">ZJ Ren</name></author><author><name sortKey="Tang, Jh" uniqKey="Tang J">JH Tang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farooqi, Aa" uniqKey="Farooqi A">AA Farooqi</name></author><author><name sortKey="Tabassum, S" uniqKey="Tabassum S">S Tabassum</name></author><author><name sortKey="Ahmad, A" uniqKey="Ahmad A">A Ahmad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beg, Ms" uniqKey="Beg M">MS Beg</name></author><author><name sortKey="Brenner, Aj" uniqKey="Brenner A">AJ Brenner</name></author><author><name sortKey="Sachdev, J" uniqKey="Sachdev J">J Sachdev</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghandadi, M" uniqKey="Ghandadi M">M Ghandadi</name></author><author><name sortKey="Sahebkar, A" uniqKey="Sahebkar A">A Sahebkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akao, Y" uniqKey="Akao Y">Y Akao</name></author><author><name sortKey="Noguchi, S" uniqKey="Noguchi S">S Noguchi</name></author><author><name sortKey="Iio, A" uniqKey="Iio A">A Iio</name></author><author><name sortKey="Kojima, K" uniqKey="Kojima K">K Kojima</name></author><author><name sortKey="Takagi, T" uniqKey="Takagi T">T Takagi</name></author><author><name sortKey="Naoe, T" uniqKey="Naoe T">T Naoe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lai, M" uniqKey="Lai M">M Lai</name></author><author><name sortKey="Du, G" uniqKey="Du G">G Du</name></author><author><name sortKey="Shi, R" uniqKey="Shi R">R Shi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Y" uniqKey="Li Y">Y Li</name></author><author><name sortKey="Gong, P" uniqKey="Gong P">P Gong</name></author><author><name sortKey="Hou, Jx" uniqKey="Hou J">JX Hou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kastl, L" uniqKey="Kastl L">L Kastl</name></author><author><name sortKey="Brown, I" uniqKey="Brown I">I Brown</name></author><author><name sortKey="Schofield, Ac" uniqKey="Schofield A">AC Schofield</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogawa, T" uniqKey="Ogawa T">T Ogawa</name></author><author><name sortKey="Saiki, Y" uniqKey="Saiki Y">Y Saiki</name></author><author><name sortKey="Shiga, K" uniqKey="Shiga K">K Shiga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ren, F" uniqKey="Ren F">F Ren</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Liang, H" uniqKey="Liang H">H Liang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Dan, G" uniqKey="Dan G">G Dan</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Wei, C" uniqKey="Wei C">C Wei</name></author><author><name sortKey="Guo, Cc" uniqKey="Guo C">CC Guo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, J" uniqKey="Gao J">J Gao</name></author><author><name sortKey="Li, N" uniqKey="Li N">N Li</name></author><author><name sortKey="Dong, Y" uniqKey="Dong Y">Y Dong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hiyoshi, Y" uniqKey="Hiyoshi Y">Y Hiyoshi</name></author><author><name sortKey="Schetter, Aj" uniqKey="Schetter A">AJ Schetter</name></author><author><name sortKey="Okayama, H" uniqKey="Okayama H">H Okayama</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rapti, Sm" uniqKey="Rapti S">SM Rapti</name></author><author><name sortKey="Kontos, Ck" uniqKey="Kontos C">CK Kontos</name></author><author><name sortKey="Christodoulou, S" uniqKey="Christodoulou S">S Christodoulou</name></author><author><name sortKey="Papadopoulos, In" uniqKey="Papadopoulos I">IN Papadopoulos</name></author><author><name sortKey="Scorilas, A" uniqKey="Scorilas A">A Scorilas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agostini, M" uniqKey="Agostini M">M Agostini</name></author><author><name sortKey="Knight, Ra" uniqKey="Knight R">RA Knight</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31040703</article-id><article-id pub-id-type="pmc">6462170</article-id><article-id pub-id-type="doi">10.2147/OTT.S188054</article-id><article-id pub-id-type="publisher-id">ott-12-2649</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yongchao</given-names></name><xref ref-type="aff" rid="af1-ott-12-2649">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Changfeng</given-names></name><xref ref-type="aff" rid="af2-ott-12-2649">2</xref><xref ref-type="corresp" rid="c1-ott-12-2649"></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dandan</given-names></name><xref ref-type="aff" rid="af2-ott-12-2649">2</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="af2-ott-12-2649">2</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Jingpeng</given-names></name><xref ref-type="aff" rid="af2-ott-12-2649">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bin</given-names></name><xref ref-type="aff" rid="af2-ott-12-2649">2</xref></contrib></contrib-group><aff id="af1-ott-12-2649"><label>1</label>Department of Gastrointestinal Surgery, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China</aff><aff id="af2-ott-12-2649"><label>2</label>Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China,<email>changfengli1975@163.com</email></aff><author-notes><corresp id="c1-ott-12-2649">Correspondence: Changfeng Li, Department of Endoscopy Center, China–Japan Union Hospital of Jilin University, No.126, Xiantai Street, Changchun, Jilin 130033, China, Tel +86 431 8464 1026, Email <email>changfengli1975@163.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>09</day><month>4</month><year>2019</year></pub-date><volume>12</volume><fpage>2649</fpage><lpage>2660</lpage><permissions><copyright-statement>© 2019 Li et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2019</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The chemoresistance of colon cancer to oxaliplatin (L-OHP) indicates poor prognosis. Long non-coding RNA (lncRNA) KCNQ1OT1 (KCNQ1 opposite strand/antisense transcript 1) has been shown to participate in the tumorigenesis of several types of cancers. However, little is known about the role of KCNQ1OT1 in the chemoresistance and prognosis of colon cancer.</p></sec><sec><title>Materials and methods</title><p>Quantitative-PCR and Western blot were used to measure the expression profiles of KCNQ1OT1, miR-34a, and Atg4B in colon cancer tissues and cells. Cell viability assay and flow cytometry were used to examine their effects on cell proliferation and death. Cleavage of LC3 and GFP-LC3 plasmid transfection were used to detect autophagic activity. Double luciferase reporter assay was used to verify the interactions between miRNA and lncRNA or mRNA. Xenograft tumor model was used to verify the effects of KCNQ1OT1 in vivo.</p></sec><sec><title>Results</title><p>In this study, it is shown that the expression level of KCNQ1OT1 was increased in tumor, which indicated poor prognosis in colon cancer patients. Using colon cancer cell lines HCT116 and SW480, it was demonstrated that knockdown of KCNQ1OT1 decreased the cell viability and increased the apoptosis rates upon L-OHP treatment. Further studies indicated that Atg4B upregulation was partially responsible for KCNQ1OT1-induced protective autophagy and chemoresistance. Moreover, miR-34a functioned as a bridge between KCNQ1OT1 and Atg4B, which could be sponged by KCNQ1OT1, while it could also bind to the 3′-UTR of Atg4B and downregulate its expressions. Finally, we show that the KCNQ1OT1/miR-34a/Atg4B axis regulated the chemoresistance of colon cancer cells in vitro and in vivo.</p></sec><sec><title>Conclusion</title><p>lncRNA KCNQ1OT1 promoted the chemoresistance of colon cancer by sponging miR-34a, thus upregulating the expressions of Atg4B and enhancing protective autophagy. KCNQ1OT1 might become a promising target for colon cancer therapeutics.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>KCNQ1OT1</kwd><kwd>colorectal cancer</kwd><kwd>protective autophagy</kwd><kwd>miR-34a</kwd><kwd>Atg4B</kwd><kwd>chemoresistance</kwd></kwd-group></article-meta></front><floats-group><fig id="f1-ott-12-2649" position="float"><label>Figure 1</label><caption><p>The expression profiles of lncRNA KCNQ1OT1 in colon cancer patients and the correlation with prognosis.</p><p><bold>Notes:</bold> (<bold>A</bold>) The expression levels of KCNQ1OT1 in colon cancer tissues and corresponding adjacent tissues were detected by qRT-PCR. **<italic>P</italic><0.01. (<bold>B</bold>) The expression levels of KCNQ1OT1 in the tumor tissues of stage I/II and stage III/IV patients. ***<italic>P</italic><0.0001. (<bold>C</bold>) The fold changes of KCNQ1OT1 expression level in each patient were measured. (<bold>D</bold>) Kaplan–Meier curves of overall survival and log-rank test of patients with low and high KCNQ1OT1 expression levels. *<italic>P</italic><0.05. (<bold>E</bold>) HCT116 and SW480 cells were transfected with KCNQ1OT1 siRNA and negative control, and then the cell viability assay was conducted with different concentrations of L-OHP. *<italic>P</italic><0.05. (<bold>F</bold> and <bold>G</bold>) The apoptosis rates of colon cancer cells were measured by flow cytometry. *<italic>P</italic><0.05 and ***<italic>P</italic><0.0001. Data are presented as mean ± SEM.</p><p><bold>Abbreviations:</bold> L-OHP, oxaliplatin; lncRNA, long non-coding RNA; PI, propidium iodide; qRT-PCR, quantitative real-time PCR; ns, not significant.</p></caption><graphic xlink:href="ott-12-2649Fig1"></graphic></fig><fig id="f2-ott-12-2649" position="float"><label>Figure 2</label><caption><p>The effects of KCNQ1OT1 on L-OHP-induced protective autophagy and Atg4B expression levels in colon cancer cells.</p><p><bold>Notes:</bold> (<bold>A</bold>) HCT116 and SW480 cells were treated with L-OHP with the absence and presence of autophagy inhibitor 3-MA or CQ, and then the expression levels of PARP and LC3 were detected by Western blot, with GAPDH as a loading control. *<italic>P</italic><0.05, **<italic>P</italic><0.01, and ***<italic>P</italic><0.0001. (<bold>B</bold>) HCT116 and SW480 cells were transfected with siKCNQ1OT1 and treated with 10 μmol/L L-OHP for 24 h, and then Western blot was performed. *<italic>P</italic><0.05, **<italic>P</italic><0.01, and ***<italic>P</italic><0.0001. (<bold>C</bold>) HCT116 and SW480 cells were treated with GFP-LC3 plasmid and then 10 μmol/L L-OHP was added. After treatment, cells were observed in the fluorescence microscope. (<bold>D</bold>) HCT116 and SW480 cells were co-transfected with siNC/siKCNQ1OT1 and pcDNA/pcDNA-Atg4B plasmids, and then cell viability assay was performed as above. *<italic>P</italic><0.01 and **<italic>P</italic><0.01. (<bold>E</bold>) HCT116 and SW480 cells were treated as shown in (<bold>D</bold>), and then the apoptosis rates were measured by flow cytometry. *<italic>P</italic><0.05 and **<italic>P</italic><0.01.</p><p><bold>Abbreviations:</bold> CQ, chloroquine; L-OHP, oxaliplatin; 3-MA, 3-methyladenine; ns, not significant.</p></caption><graphic xlink:href="ott-12-2649Fig2"></graphic></fig><fig id="f3-ott-12-2649" position="float"><label>Figure 3</label><caption><p>The mechanisms of miR-34a functioning as the connection between KCNQ1OT1 and Atg4B.</p><p><bold>Notes:</bold> (<bold>A</bold>) Predicted binding site of miR-34a on the 3′-UTR of Atg4B mRNA base in the Targetscan database. (<bold>B</bold>) Western blot analysis was conducted to detect the expression levels of Atg4B, transfected with miR-34a mimic and NC. N=3, *<italic>P</italic><0.05 and ***<italic>P</italic><0.0001. (<bold>C</bold>) Double luciferase reporter assay results of the interaction between miR-34a and the 3′-UTR of Atg4B mRNA. N=3, *<italic>P</italic><0.05. (<bold>D</bold>) Predicted miR-34a binding sites in KCNQ1OT1 sequence based on the DIANA-LncBase analysis. (<bold>E</bold>) The expression level of miR-34a was measured by qRT-PCR after being transfected with KCNQ1OT1 siRNA for 48 h. N=3, *<italic>P</italic><0.05 and **<italic>P</italic><0.01. (<bold>F</bold>) The double luciferase reporter assay experiments investigating the binding affinity of miR-34a to KCNQ1OT1. *<italic>P</italic><0.05 and **<italic>P</italic><0.01. (<bold>G</bold>) Cell viability assay of miR-34a mimic or inhibitor on colon cancer cells. N=3, *<italic>P</italic><0.05. (<bold>H</bold>) HCT116 and SW480 cells were treated as shown in (<bold>G</bold>), and then apoptosis rates were measured using flow cytometry. N=3, *<italic>P</italic><0.05 and **<italic>P</italic><0.01.</p><p><bold>Abbreviations:</bold> L-OHP, oxaliplatin; qRT-PCR, quantitative real-time PCR; ns, not significant.</p></caption><graphic xlink:href="ott-12-2649Fig3"></graphic></fig><fig id="f4-ott-12-2649" position="float"><label>Figure 4</label><caption><p>The effects of KCNQ1OT1/miR-34a/Atg4B axis in regulating the sensitivity of colon cancer cells to L-OHP in vitro and in vivo.</p><p><bold>Notes:</bold> (<bold>A</bold> and <bold>B</bold>) HCT116 and SW480 cells were cotransfected with siNC/siKCNQ1OT1 and miR-34a NC/miR-34a inhibitors for 24 h, and then L-OHP was added and Western blot performed. N=3, *<italic>P</italic><0.05, **<italic>P</italic><0.01, and ***<italic>P</italic><0.0001. (<bold>C</bold> and <bold>D</bold>) Colon cancer cells were treated as shown in (<bold>A</bold>), and then the cell viability and apoptosis rates were measured by CCK-8 and flow cytometry. *<italic>P</italic><0.05. (<bold>E</bold>) HCT116 and SW480 cells were pre-transfected with KCNQ1OT1 siRNA or siNC, and then the cells were injected subcutaneously to build the xenograft tumor model. **<italic>P</italic><0.01 and ***<italic>P</italic><0.0001. (<bold>F</bold>) The expression levels of miR-34a were measured by qRT-PCR in xenograft tumor. *<italic>P</italic><0.05 and **<italic>P</italic><0.01. (<bold>G</bold> and <bold>H</bold>) The expression levels of PARP, Atg4B, and LC3 were detected by Western blot in the xenograft tumor tissues, and the bands were analyzed. **<italic>P</italic><0.01 and ***<italic>P</italic><0.0001.</p><p><bold>Abbreviations:</bold> CCK-8, Cell Counting Kit-8; L-OHP, oxaliplatin; qRT-PCR, quantitative real-time PCR.</p></caption><graphic xlink:href="ott-12-2649Fig4"></graphic></fig><table-wrap id="t1-ott-12-2649" position="float"><label>Table 1</label><caption><p>The Cox’s proportional hazards analysis of the overall survival in colon cancer patients</p></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Characteristics</th><th colspan="3" valign="top" align="left" rowspan="1">Univariate analysis</th><th colspan="3" valign="top" align="left" rowspan="1">Multivariate analysis</th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">HRs</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-values</th><th valign="top" align="left" rowspan="1" colspan="1">HRs</th><th valign="top" align="left" rowspan="1" colspan="1">95% CI</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1">1.068</td><td valign="top" align="left" rowspan="1" colspan="1">0.416, 2.746</td><td valign="top" align="left" rowspan="1" colspan="1">0.891</td><td valign="top" align="left" rowspan="1" colspan="1">0.570</td><td valign="top" align="left" rowspan="1" colspan="1">0.134, 2.428</td><td valign="top" align="left" rowspan="1" colspan="1">0.448</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">0.961</td><td valign="top" align="left" rowspan="1" colspan="1">0.892, 1.036</td><td valign="top" align="left" rowspan="1" colspan="1">0.301</td><td valign="top" align="left" rowspan="1" colspan="1">1.020</td><td valign="top" align="left" rowspan="1" colspan="1">0.919, 1.133</td><td valign="top" align="left" rowspan="1" colspan="1">0.708</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor size</td><td valign="top" align="left" rowspan="1" colspan="1">1.569</td><td valign="top" align="left" rowspan="1" colspan="1">1.158, 2.126</td><td valign="top" align="left" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="tfn2-ott-12-2649">**</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.551</td><td valign="top" align="left" rowspan="1" colspan="1">0.563, 4.272</td><td valign="top" align="left" rowspan="1" colspan="1">0.396</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor stage (Dukes)</td><td valign="top" align="left" rowspan="1" colspan="1">0.245</td><td valign="top" align="left" rowspan="1" colspan="1">0.072, 0.835</td><td valign="top" align="left" rowspan="1" colspan="1">0.025<xref ref-type="table-fn" rid="tfn1-ott-12-2649">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.004</td><td valign="top" align="left" rowspan="1" colspan="1">0.000, 0.255</td><td valign="top" align="left" rowspan="1" colspan="1">0.009<xref ref-type="table-fn" rid="tfn2-ott-12-2649">**</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymphatic metastasis</td><td valign="top" align="left" rowspan="1" colspan="1">0.360</td><td valign="top" align="left" rowspan="1" colspan="1">0.139, 0.934</td><td valign="top" align="left" rowspan="1" colspan="1">0.036<xref ref-type="table-fn" rid="tfn1-ott-12-2649">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">55.899</td><td valign="top" align="left" rowspan="1" colspan="1">0.707, 4,422.065</td><td valign="top" align="left" rowspan="1" colspan="1">0.071</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Distant metastasis</td><td valign="top" align="left" rowspan="1" colspan="1">0.276</td><td valign="top" align="left" rowspan="1" colspan="1">0.087, 0.873</td><td valign="top" align="left" rowspan="1" colspan="1">0.028<xref ref-type="table-fn" rid="tfn1-ott-12-2649">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.365</td><td valign="top" align="left" rowspan="1" colspan="1">0.285, 100.896</td><td valign="top" align="left" rowspan="1" colspan="1">0.262</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">KCNQ1OT1 expression levels</td><td valign="top" align="left" rowspan="1" colspan="1">6.056</td><td valign="top" align="left" rowspan="1" colspan="1">2.678, 13.694</td><td valign="top" align="left" rowspan="1" colspan="1">0.000<xref ref-type="table-fn" rid="tfn3-ott-12-2649">***</xref></td><td valign="top" align="left" rowspan="1" colspan="1">5.581</td><td valign="top" align="left" rowspan="1" colspan="1">1.173, 26.562</td><td valign="top" align="left" rowspan="1" colspan="1">0.031<xref ref-type="table-fn" rid="tfn1-ott-12-2649">*</xref></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn1-ott-12-2649"><label>*</label><p><italic>P</italic><0.05,</p></fn><fn id="tfn2-ott-12-2649"><label>**</label><p><italic>P</italic><0.01, and</p></fn><fn id="tfn3-ott-12-2649"><label>***</label><p><italic>P</italic><0.0001.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ott-12-2649" position="float"><label>Table 2</label><caption><p>Correlation between KCNQ1OT1 expression and clinicopathological features of colon cancer patients</p></caption><table frame="box" rules="all"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="left" rowspan="1" colspan="1">Low KCNQ1OT1 (N=25)</th><th valign="top" align="left" rowspan="1" colspan="1">High KCNQ1OT1 (N=20)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>P</italic>-values</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.216</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.50</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥50</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> <50</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor size (cm)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.036<xref ref-type="table-fn" rid="tfn4-ott-12-2649">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> <3</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥3</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tumor stage (Dukes)</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="tfn4-ott-12-2649">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> I, II</td><td valign="top" align="left" rowspan="1" colspan="1">18</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> III, IV</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymphatic metastasis (yes)</td><td valign="top" align="left" rowspan="1" colspan="1">7</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">0.003<xref ref-type="table-fn" rid="tfn4-ott-12-2649">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Distant metastasis (yes)</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">0.435</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Note:</bold></p></fn><fn id="tfn4-ott-12-2649"><label>*</label><p><italic>P</italic><0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Jin, Jingpeng" sort="Jin, Jingpeng" uniqKey="Jin J" first="Jingpeng" last="Jin">Jingpeng Jin</name><name sortKey="Li, Changfeng" sort="Li, Changfeng" uniqKey="Li C" first="Changfeng" last="Li">Changfeng Li</name><name sortKey="Li, Dandan" sort="Li, Dandan" uniqKey="Li D" first="Dandan" last="Li">Dandan Li</name><name sortKey="Yang, Lei" sort="Yang, Lei" uniqKey="Yang L" first="Lei" last="Yang">Lei Yang</name><name sortKey="Zhang, Bin" sort="Zhang, Bin" uniqKey="Zhang B" first="Bin" last="Zhang">Bin Zhang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Li, Yongchao" sort="Li, Yongchao" uniqKey="Li Y" first="Yongchao" last="Li">Yongchao Li</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000228 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000228 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:6462170
|texte= lncRNA KCNQ1OT1 enhances the chemoresistance of oxaliplatin in colon cancer by targeting the miR-34a/ATG4B pathway
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:31040703" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |